A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH-RISK CUTANEOUS SQUAMOUS CELL CARCINOMA
Study of Cemiplimab in Cutaneous Squamous Cell Carcinoma
Sponsor: Regeneron Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS4125
U.S. Govt. ID: NCT03969004
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is determine if cemiplimab will prevent Cutaneous Squamous Cell Cancer (CSCC) from returning after surgery and radiation.
Investigator
Shaheer Khan, DO
Do You Qualify?
Are you 18 years of age or older? Yes No
Were you diagnosed with Cutaneous Squamous Cell Cancer (CSCC)? Yes No
Are you able to understand and complete study-related questionnaires? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162